Scholarlink

<p>The role of consolidative radiotherapy (RT) in the upfront management of patients with early-stage classic Hodgkin lymphoma (cHL) is a&#xa0;subject of debate. Particularly, its impact on preventing relapses and the subsequent necessity of salvage autologous stem cell transplantation (ASCT). We analyzed in this multicenter retrospective study data of patients with early-stage cHL. The study evaluates whether the omission of RT increases the risk of relapse and consequently the need for ASCT. Relapse rates and frequency of ASCT were compared between patients who got combined modality treatment (CMT) versus chemotherapy alone. A total of 490 patients (median age 27, mean follow-up 59 months) were included, with 57.8% receiving CMT. Relapse rates in chemotherapy alone and the CMT cohort were 10.6% and 8.5% (<i>p</i> = 0.92), respectively. Frequency of ASCT in chemotherapy alone and CMT arm were 3.9% and 5.3% (<i>p</i> = 0.19), respectively. Post-ASCT complete metabolic remission rate was similar (80% in CMT vs 75% in chemotherapy alone; <i>p</i> = 0.78). Five-year overall survival rate was not different (HR: 1.03; <i>p</i> = 0.95). Our real-world data suggests that omission of routine consolidative RT in patients with early-stage cHL does not increase the risk of relapse or the likelihood of undergoing ASCT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Role of consolidative radiotherapy in preventing relapses and subsequent salvage ASCT in early-stage classic Hodgkin lymphoma

  • 期刊论文

  • 发表日期：

    2026年5月28日

查看全文
  • Reyad Dada,
  • John Apostolidis,
  • Refaei Belal Ibrahim,
  • Asmaa Ahmed Salem,
  • Mostafa Ibrahim Mahmoud,
  • Hafiz Asif Iqbal,
  • Tarik Boubakra,
  • Hamza Ghatasheh,
  • Azhar Nawaz,
  • Khalid Halahleh

摘要

The role of consolidative radiotherapy (RT) in the upfront management of patients with early-stage classic Hodgkin lymphoma (cHL) is a subject of debate. Particularly, its impact on preventing relapses and the subsequent necessity of salvage autologous stem cell transplantation (ASCT). We analyzed in this multicenter retrospective study data of patients with early-stage cHL. The study evaluates whether the omission of RT increases the risk of relapse and consequently the need for ASCT. Relapse rates and frequency of ASCT were compared between patients who got combined modality treatment (CMT) versus chemotherapy alone. A total of 490 patients (median age 27, mean follow-up 59 months) were included, with 57.8% receiving CMT. Relapse rates in chemotherapy alone and the CMT cohort were 10.6% and 8.5% (p = 0.92), respectively. Frequency of ASCT in chemotherapy alone and CMT arm were 3.9% and 5.3% (p = 0.19), respectively. Post-ASCT complete metabolic remission rate was similar (80% in CMT vs 75% in chemotherapy alone; p = 0.78). Five-year overall survival rate was not different (HR: 1.03; p = 0.95). Our real-world data suggests that omission of routine consolidative RT in patients with early-stage cHL does not increase the risk of relapse or the likelihood of undergoing ASCT.